AKT1 and lung carcinoma: IGFBP-3 has been suggested as a potential target for lung cancer treatment, as adenovirus-mediated overexpression of IGFBP-3 inhibited the growth of NSCLC cells in vitro and in vivo by inducing apoptosis through the inhibition of the PI3K/Akt/PKB and MAPK signalling pathways [21].